Clinical Trials
155 trialsFeasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Cedars-Sinai Medical Center
Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
City of Hope Medical Center
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
City of Hope Medical Center
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
City of Hope Medical Center
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
Calibr, a division of Scripps Research
Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
City of Hope Medical Center
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
British Columbia Cancer Agency
Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma
City of Hope Medical Center
A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
Hackensack Meridian Health
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
Ohio State University Comprehensive Cancer Center
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Massachusetts General Hospital
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
City of Hope Medical Center
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Medical College of Wisconsin
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Mayo Clinic
Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies
H. Lee Moffitt Cancer Center and Research Institute
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
UNC Lineberger Comprehensive Cancer Center
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
University of California, San Francisco
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
University of Colorado, Denver
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
University of Arizona
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Case Comprehensive Cancer Center
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma
City of Hope Medical Center
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia
City of Hope Medical Center
CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
University of Maryland, Baltimore
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia
Jonsson Comprehensive Cancer Center
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
Weill Medical College of Cornell University
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Stanford University
Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies
Roswell Park Cancer Institute
JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma
Peking University Cancer Hospital & Institute
Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma
Memorial Sloan Kettering Cancer Center
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
University of California, Davis
Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma
City of Hope Medical Center
CD19-CARNK/T
Second Affiliated Hospital, School of Medicine, Zhejiang University
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas
Stanford University
A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL
Dana-Farber Cancer Institute
ENABLE-1
Malaghan Institute of Medical Research
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
Calibr, a division of Scripps Research
Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma
Northwestern University
CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL
City of Hope Medical Center
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Ipilimumab and Local Radiation for Selected Solid Tumors
Stanford University
CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies
M.D. Anderson Cancer Center
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
Stanford University
Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma
Washington University School of Medicine
CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy
University of Pennsylvania
BRiM
Brown University
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL
Masonic Cancer Center, University of Minnesota
A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma
Memorial Sloan Kettering Cancer Center